Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Phase II Evaluation Of ONTAK (DENILEUKINDIFTITOX) In Patients With Low Or Intermediate Grade-B-Cell Non-Hodgkin's Lymphoma Who Have Been Treated Previously With A Monoclonal Antibody Or Who Are Not Candidates For Monoclonal Antibody Therapy

NCT00026429 is registered in ClinicalTrials.gov with Pharmatech Oncology as lead sponsor.

NCT NCT00026429
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00026429 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Phase II Evaluation Of ONTAK (DENILEUKINDIFTITOX) In Patients With Low Or Intermediate Grade-B-Cell Non-Hodgkin's Lymphoma Who Have Been Treated Previously With A Monoclonal Antibody Or Who Are Not Candidates For Monoclonal Antibody Therapy
Lead sponsor
Pharmatech Oncology
Phase
Phase 2
Overall status
Unknown status
Start date
January 31, 2001
Completion date
Not reported
Enrollment
Not reported
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia, lymphoma